nvg-2089
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 25, 2025 (NCT07027111)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07095127 | Phase 2 | Sep 30, 2025 | Nuvig Therapeutics, Inc. |
| NCT07027111 | Phase 2 | Apr 25, 2025 | Nuvig Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nuvig Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1